Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methysergide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 11/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | CASP6 | P55212 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methysergide SCHEMBL28196309 | 1.00 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| Methysergide SCHEMBL21803661 | 1.00 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| Methysergide SCHEMBL29408580 | 1.00 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| Methysergide SCHEMBL467884 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| Methysergide SCHEMBL29359107 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| Methysergide SCHEMBL467883 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| Methysergide SCHEMBL41843 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| Methysergide SCHEMBL28086572 | 0.94 | KMT2A (0.98) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| Methysergide SCHEMBL7088235 | 0.94 | KMT2A (0.98) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| Methsergide SCHEMBL29601488 | 0.91 | KMT2A (0.91) | KMT2AALDH1A1MEN1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1679 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| WO-2023124923-A1 | METHOD FOR DETERMINING SALT FORMING RATE IN RAW MATERIAL, I.E., METHYLERGONOVINE MALEATE | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 2023-07-06 | — | — | WO | claimed |
| US-11034751-B1 | Methods and compositions for treating cancer using serotonin receptor inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-15 | — | — | US | claimed |
| WO-2021078412-A1 | FRACTAL FORMULATIONS | MESSADEK JALLAL (BE) | 2021-04-29 | — | — | WO | claimed |
| US-20200147076-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-05-14 | — | — | US | claimed |
| US-20200095627-A1 | MOLECULAR SENSORS AND USES THEREOF | NEW YORK UNIVERSITY | 2020-03-26 | — | — | US | claimed |
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2019-01-03 | — | — | US | claimed |
| US-20180296556-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2018-10-18 | — | — | US | claimed |
| US-20170172971-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2017-06-22 | — | — | US | claimed |
| US-20160220505-A1 | COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION | SOLUBEST LTD. (IL) | 2016-08-04 | — | — | US | claimed |
| JP-2000507544-A | — | — | 2000-06-20 | — | — | JP | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| US-6043244-A | Method and composition for treating migraine | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-03-28 | — | — | US | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| EP-0932416-A2 | METHOD AND POTENTIATED COMPOSITION FOR TREATING MIGRAINE | Algos Pharmaceutical Corporation (US) | 1999-08-04 | — | — | EP | claimed |
| EP-0906104-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-04-07 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| WO-1998015275-A2 | METHOD AND POTENTIATED COMPOSITION FOR TREATING MIGRAINE | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-04-16 | — | — | WO | claimed |
| WO-1997035584-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-10-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | HTR1A 1441/4885HTR2C 1808/4885HTR2B 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.